+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia



Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia



Atherosclerosis 237(1): 140-145



Controversial findings exist regarding potential influence of statin therapy on diabetic incidence. Aim of this study was to investigate the role of long duration statin treatment on diabetes mellitus (DM) incidence of Heterozygous Familial Hypercholesterolemia (hFH) and Familial Combined Hyperlipidemia (FCH) patients. Study population consisted of 212 hFH and 147 FCH patients that visited Lipid Outpatient Department (mean follow up of 11 and 10 years respectively). Several clinical data such as history of DM, cardiovascular disease, thyroid function, metabolic syndrome, glucose levels, lipid profile and lifestyle data were obtained. In order to compare the effects of different doses of different types of statins, a "statin treatment intensity product" was used. 14% of FCH and only 1% of hFH patients developed DM during follow up. Although univariate analysis showed a statistical trend (p = 0.06) in the association between new onset DM and statin treatment intensity (STI) in the FCH subgroup of patients with normal baseline glucose levels, this was no longer significant after adjusting for several confounders. Furthermore, the type of statins used did not seem to play a role in the development of DM either in hFH or FCH patients. Long duration of high STI does not seem to be associated with diabetic risk in hFH patients. High STI used in the FCH population is not associated with increased risk of new onset DM compared to low STI. Further studies are required in order to clarify the potential diabetogenic effects of statins in these high risk populations.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911204

Download citation: RISBibTeXText

PMID: 25238223

DOI: 10.1016/j.atherosclerosis.2014.08.047


Related references

Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up. Angiology 69(3): 242-248, 2017

Diabetogenic effects of high intensity statin treatment in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia. Atherosclerosis 235(2): E56-E57, 2014

Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. International Journal of Cardiology 121(2): 178-183, 2006

The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia. Casopis Lekaru Ceskych 135(13): 413-416, 1996

Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology 12(1): 33-43, 2017

Overlapping of triglyceride levels in patients with familial combined hypercholesterolemia and heterozygous familial hypercholesterolemia. Journal of Inherited Metabolic Disease 24(Supplement 1): 148, 2001

Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. Journal of Lipid Research 27(7): 713-723, 1986

Evolution of thoracic aorta atherosclerosis in patients with heterozygous familial hypercholesterolemia after statin therapy. Journal of the American College of Cardiology 31(2 SUPPL A): 281A, 1998

Apolipoprotein B is associated with metabolic syndrome in Chinese families with familial combined hyperlipidemia, familial hypertriglyceridemia and familial hypercholesterolemia. International Journal of Cardiology 116(2): 194-200, 2006

Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185(2): 307-312, 2005

Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia. Annals of Clinical and Laboratory Science 36(3): 353-355, 2006

Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment. Current Opinion in Lipidology 2019, 2019

Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. Journal of the American Heart Association 2(2): E000028, 2013

Combination drug therapy for treatment of patients with familial combined hyperlipidemia resulting in combined hypertriglyceridemia and hypercholesterolemia. American Heart Association Monograph (124): II-200, 1986

Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: Correlation with high density lipoproteins. Journal of the American College of Cardiology 27(7): 1562-1570, 1996